AOP Orphan and Rigi Healthcare Start Rigi Orphan Inc., USA
![](/46/pdcnewsitem/03/43/58/9oTJ28VIREPkQg2.gif)
AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, have announced the creation of Rigi Orphan Inc, USA. The new company will focus on the development, in-licensing and commercialization of pharmaceutical specialties for rare diseases in North America.
"We are proud to continue our expansion strategy by targeting the US market together with Rigi Healthcare, the best possible partner for that endeavor. Rigi Healthcare has assembled a highly experienced team ideally positioned to build commercial operations and support the promotion of AOP’s products in the US as part of a broader orphan portfolio," said Dr Rudolf Widmann, owner and CEO of AOP Orphan.
"There are still many diseases with high unmet medical need and our priority is to provide better care for these patients in the US. Our partner, AOP Orphan, is a European leader dedicated to that segment who will contribute products as well as development and marketing expertise to the new company. We are looking forward to working with Dr Widmann and his team to continue advancing the pipeline of innovative treatments,” said Hans Peter Hasler.
Hans Peter Hasler will be the Chairman of Rigi Orphan Inc while Dr Rudolf Widman will join its board of Directors. The company is in the process of complementing AOP’s portfolio with additional innovative products.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance